NASDAQ: NXGLNexgel Inc Stock
$3.25-0.06 (-1.81%)
Updated Feb 10, 2025
NXGL Price
$3.25
Fair Value Price
N/A
Market Cap
$22.07M
52 Week Low
$1.84
52 Week High
$5.10
P/E
-5.51x
P/B
4.71x
P/S
2.52x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.73M
Earnings
-$3.53M
Gross Margin
31.6%
Operating Margin
-51.46%
Profit Margin
-52.5%
Debt to Equity
1.19
Operating Cash Flow
-$4M
Beta
0.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NXGL Overview
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the U.S. The company has formulated more than 200 different hydrogel combinations to bring natural ingredients to skin patches so that they can be worn for long periods of time with little to no irritation. Formerly AquaMed Technologies, Inc., NEXGEL was founded in 1997 and is based in Langhorne, PA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NXGL's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Value
B
Growth
C
Momentum
D
Sentiment
C
Safety
F
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
A
NXGL
Ranked#42 of 49
Ranked#42 of 49
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.12 | A | |
| $33.25 | A | |
| $4.65 | A |
Be the first to know about important NXGL news, forecast changes, insider trades & much more!
NXGL News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NXGL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NXGL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NXGL is poor value based on its book value relative to its share price (4.71x), compared to the US Medical Instruments & Supplies industry average (4.11x)
P/B vs Industry Valuation
NXGL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NXGL due diligence checks available for Premium users.
Valuation
NXGL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.51x
Industry
40.12x
Market
31x
NXGL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.71x
Industry
4.11x
NXGL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NXGL's financial health
Profit margin
Revenue
$2.9M
Net Income
-$693.0k
Profit Margin
-23.6%
NXGL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NXGL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.6M
Liabilities
$5.6M
Debt to equity
1.19
NXGL's short-term assets ($4.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NXGL's short-term assets ($4.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NXGL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NXGL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
-$8.0k
Financing
$1.2M
NXGL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NXGL vs Medical Stocks
Nexgel Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.